Marshall Wace LLP Cuts Stake in CVRx, Inc. (NASDAQ:CVRX)

Marshall Wace LLP decreased its stake in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 60.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,202 shares of the company's stock after selling 69,487 shares during the quarter. Marshall Wace LLP owned approximately 0.19% of CVRx worth $585,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in CVRX. JPMorgan Chase & Co. raised its stake in CVRx by 10,520.1% during the 4th quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock worth $7,960,000 after acquiring an additional 622,370 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of CVRx during the 4th quarter valued at $455,000. Barclays PLC lifted its stake in shares of CVRx by 312.5% during the 3rd quarter. Barclays PLC now owns 19,067 shares of the company's stock valued at $169,000 after buying an additional 14,445 shares in the last quarter. Jane Street Group LLC boosted its holdings in CVRx by 36.1% in the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company's stock worth $168,000 after buying an additional 5,053 shares during the period. Finally, Geode Capital Management LLC increased its stake in CVRx by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company's stock worth $2,600,000 after buying an additional 6,443 shares in the last quarter. 75.27% of the stock is owned by hedge funds and other institutional investors.

CVRx Trading Up 1.6 %

CVRX stock traded up $0.12 during mid-day trading on Thursday, reaching $7.60. 28,220 shares of the stock traded hands, compared to its average volume of 311,980. The business has a 50-day moving average price of $9.53 and a two-hundred day moving average price of $12.64. The stock has a market capitalization of $198.03 million, a PE ratio of -2.83 and a beta of 1.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.23 and a current ratio of 12.06. CVRx, Inc. has a one year low of $5.81 and a one year high of $18.55.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. Equities research analysts expect that CVRx, Inc. will post -1.91 EPS for the current year.

Wall Street Analysts Forecast Growth

CVRX has been the subject of a number of research analyst reports. Piper Sandler increased their price objective on shares of CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a report on Wednesday, February 5th. Craig Hallum lifted their price target on shares of CVRx from $20.00 to $22.00 and gave the company a "buy" rating in a report on Friday, January 17th. Canaccord Genuity Group dropped their price objective on shares of CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. Lake Street Capital decreased their target price on CVRx from $19.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, April 8th. Finally, William Blair upgraded CVRx from a "market perform" rating to an "outperform" rating in a report on Tuesday, January 14th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CVRx has an average rating of "Buy" and an average price target of $17.60.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.